Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets.
During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ...
Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog.
Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.
The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, ...
TORONTO, April 22, 2013 — MaRS Innovation, a Centre of Excellence for Commercialization and Research, today announced the formation of a strategic partnership with Pfizer Inc. to advance early-stage technologies related to human health in therapeutics and diagnostics.
Through this collaboration, MaRS Innovation and Pfizer will jointly identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
“There’s growing consensus that transferring technologies from the university lab ...
Dr. Rafi Hofstein is among the experts featured in this month's "One question, three experts" post on the MaRS Discovery District blog.
This regular feature addresses some of the challenges that start-ups face by asking three experts to respond to a different question each month — anything from marketing and financing guidance to advice on partnerships and mentors.
Here's Hofstein's response:
The first question to define is “partnership with whom?”
You will face very different issues when, for example, partnering with another founder to create ...
MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.
This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire ...
TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.
“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ...
MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences technologies during the early stages of pharmaceutical and medical device development.
The Translational Innovation Partnership Program (TIPP) is the first co-funding agreement of its kind for MI. (more…)